文献速递甲状腺疾病

原发性甲状腺癌与转移灶中TERT、BRAF和NRAS突变分析

TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

研究分析204例甲状腺癌患者(主要为甲状腺乳头状癌180例)的437份组织样本,包括196份淋巴结转移灶和56份远处转移灶(均为放射性碘难治性转移组织)。原发灶与淋巴结转移灶间各基因一致性高,而远处转移灶中TERT启动子突变频率升高、BRAF突变频率降低。

要点

  • 原发甲状腺乳头状癌、淋巴结转移灶、远处转移灶中TERT启动子突变频率分别为12.9%、10.5%、52.4%。
  • 原发灶与淋巴结转移灶间各基因型一致性高,尤其BRAF突变型甲状腺乳头状癌。
  • 原发灶与远处转移灶总体一致性低,远处转移灶TERT启动子突变富集、BRAF突变减少,BRAF突变常与TERT启动子突变共存。

核心结论

  • 原发肿瘤与淋巴结转移灶间所有研究基因的一致性高,而远处转移灶显示TERT启动子突变富集和BRAF突变减少,TERT启动子突变可能在远处转移中起作用。

研究设计与样本

  • 对204例患者(主要为甲状腺乳头状癌,n=180)的437份组织样本进行突变分析,包括196份淋巴结转移灶和56份远处转移灶,所有远处转移灶均为放射性碘难治性转移组织。

主要发现

  • 原发甲状腺乳头状癌、淋巴结转移灶和远处转移灶中TERT启动子突变频率分别为12.9%、10.5%和52.4%。
  • 原发甲状腺乳头状癌、淋巴结转移灶和远处转移灶中BRAF突变频率分别为44.6%、41.7%和23.8%。
  • 原发甲状腺乳头状癌、淋巴结转移灶和远处转移灶中NRAS突变频率分别为1.2%、1.3%和14.3%。
  • 原发肿瘤基因型与对应淋巴结转移灶间所有基因均显示显著一致性,尤其BRAF突变型甲状腺乳头状癌。
  • 原发肿瘤与相应远处转移灶间总体一致性低;在甲状腺乳头状癌患者中,与配对原发灶相比,远处转移灶TERT启动子突变频率高、BRAF突变频率低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Little is known about the frequency of key mutations in thyroid cancer metastases and its relationship with the primary tumor genotype. OBJECTIVES: To evaluate the frequency of TERT promoter (TERTp), BRAF, and NRAS mutations in metastatic thyroid carcinomas, analyzing primary thyroid tumors, lymph node metastases (LNMs), and distant metastases. DESIGN AND PATIENTS: Mutation analysis was performed in 437 tissue samples from 204 patients, mainly with papillary thyroid carcinomas (PTCs; n = 180), including 196 LNMs and 56 distant metastases. All the distant metastases included corresponded to radioiodine-refractory metastatic tissue. RESULTS: We found the following mutation frequency in primary PTCs, LNMs, and distant metastases, respectively: TERTp: 12.9%, 10.5%, and 52.4%; BRAF: 44.6%, 41.7%, and 23.8%; and NRAS: 1.2%, 1.3%, and 14.3%. There was a significant concordance between the primary tumor genotype and the corresponding LNM for all the genes, in particular BRAF-mutated PTC. The overall concordance between primary tumors and respective distant metastases was low. In the group of patients with PTCs, we found a high frequency of TERTp mutations and a low frequency of BRAF mutations in distant metastases, in comparison with the paired primary tumors. When present in distant metastases, BRAF mutations frequently coexisted with TERTp mutations. CONCLUSIONS: When the genotype of primary tumors is compared with the genotype of LNMs, the concordance is high for all the genes studied. On the other hand, distant metastases show an enrichment in TERTp mutations and a decrease in BRAF mutations. TERTp mutations may play a role in distant metastases.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Melo M, Gaspar da Rocha A, Batista R, et al. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. J Clin Endocrinol Metab. 2017. PMID: 28323937. doi:10.1210/jc.2016-2785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。